Pasoglou V, et al. - Data were estimated to quantify the trend of metastatic deposit in recurrent prostate cancer (PCa). Researchers assessed whole-body magnetic resonance imaging (WB-MRI) trials of those with a rising prostate-specific antigen (PSA) for disease recurrence (after radical treatment by surgery or/and radiotherapy). Based on the primary treatment, patients were separated into 1) treated by radical prostatectomy without radiotherapy and with/without lymph node dissection (RP), 2) treated only by radiotherapy or hormono-radiotherapy (RT), and 3) treated with radical prostatectomy and adjuvant or salvage radiotherapy (RP + RT). They found no impact of primary treatment (RP, RT, RP + RT), Gleason score, PSA at relapse, the time between first diagnosis and recurrence on the metastatic status (oligo vs polymetastatic). The oligometastatic patients presented with a distinct distribution of bone metastases when compared to the polymetastatic cases. This distribution was not impacted by the primary treatment.